Strep Throat Treatment Market Report 2025

This Strep Throat Treatment market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The strep throat treatment market size has grown strongly in recent years. It will grow from $2.08 billion in 2024 to $2.21 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to the rising prevalence of streptococcal infections, increased awareness and diagnosis, antibiotic accessibility, healthcare infrastructure, government health initiatives, a rising pediatric population, and economic growth.

The strep throat treatment market size is expected to see strong growth in the next few years. It will grow to $2.77 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to emerging antibiotic resistance, telemedicine adoption, global health initiatives, an aging population, healthcare access in developing regions, and pharmaceutical R&D investments. Major trends in the forecast period include telemedicine integration, rapid diagnostic test innovation, AI and machine learning, antibiotic development, biotechnology advances, wearable health technology, e-pharmacies, and digital health.

The growing incidence of bacterial infections is expected to drive the expansion of the strep throat treatment market. Bacterial infections occur when harmful bacteria invade the body, multiply, and produce toxins. Contributing factors to the rise in bacterial infections include antibiotic overuse, global travel, urbanization, poor hygiene, and healthcare-associated infections. Strep throat treatment plays a crucial role in addressing these infections by offering effective medication and care, which helps alleviate symptoms, shorten the duration of illness, and prevent complications, while also aiding healthcare providers in managing patient outcomes and curbing the spread of infections. For instance, in June 2023, a report from the Office for Health Improvement and Disparities, a UK-based governmental body, revealed that 4,622 notifications of scarlet fever caused by Group A Streptococcus bacteria were recorded from week 37 to week 46 during the 2022-2023 season in England, with 851 notifications in week 46 alone. This is significantly higher than the five-year average of 1,294 notifications (ranging from 258 to 2,008) for the same period. As a result, the rising incidence of bacterial infections is contributing to the growth of the strep throat treatment market.

Major companies in the strep throat treatment market are focusing on developing innovative solutions, such as rapid throat infection diagnostics, to offer fast, accurate, and multiplex diagnostic testing for respiratory and sore throat infections at the point of care. These advancements aim to improve patient care and reduce antibiotic misuse. Rapid throat infection diagnostics include tests like the rapid strep test, which swiftly detects the presence of group A streptococcus bacteria in the throat, allowing for timely diagnosis and treatment of strep throat. For example, in June 2024, bioMérieux, a France-based in vitro diagnostics company, introduced its BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini. This rapid diagnostic test can identify five common viral and bacterial causes of respiratory and sore throat infections, providing quick and actionable results at the point of care.

In August 2022, GSK plc, a UK-based pharmaceutical manufacturing company, acquired Affinivax, Inc. for approximately $3.3 billion. This acquisition is designed to enhance GSK's portfolio of novel vaccines, with a particular focus on advancing next-generation pneumococcal vaccines through the innovative MAPSTM technology platform. Affinivax, Inc., a U.S.-based biopharmaceutical company, specializes in the development of vaccines for infectious and immune-mediated diseases.

Major companies operating in the strep throat treatment market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc (GSK), C.H. Boehringer Sohn AG And Co. KG, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Reckitt Benckiser Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals, Eisai Co. Ltd., Mylan N.V.

North America was the largest region in the strep throat treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the strep throat treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the strep throat treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Strep throat is caused by Group A Streptococcus bacteria, leading to infection primarily in the throat and tonsils. Symptoms include sore throat, difficulty swallowing, fever, swollen lymph nodes, and occasionally white patches on the tonsils. Treatment typically involves antibiotics such as penicillin or amoxicillin, along with pain relievers, rest, and fluids to manage symptoms, prevent complications, and support recovery.

Treatment for strep throat generally consists of antibiotics, pain relievers, and other supportive measures. Antibiotics are medications that kill or inhibit bacterial growth, serving as the primary treatment for strep throat by targeting the streptococcal bacteria responsible for the infection. Diagnosis methods include antibody tests, physical examinations, and throat cultures. Treatment options vary by type, including acute strep throat, pharyngitis, tonsillitis, and laryngitis, with administration routes such as oral, topical, or injectable. End users include hospitals, specialty clinics, diagnostic laboratories, and others.

The strep throat treatment market research report is one of a series of new reports that provides strep throat treatment market statistics, including strep throat treatment industry global market size, regional shares, competitors with an strep throat treatment market share, detailed strep throat treatment market segments, market trends and opportunities, and any further data you may need to thrive in the strep throat treatment industry. This strep throat treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The strep throat treatment market consists of revenues earned by entities through services such as, antibiotic prescriptions, pain relief management, supportive care, and follow-up consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The strep throat treatment market also includes sales of throat lozenges and supportive care items such as throat sprays and herbal remedies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.